Hemogenyx Pharmaceuticals Plc (LON:HEMO)

Market Cap	31.28M -59.5%
Revenue (ttm)	n/a
Net Income	-9.76M
EPS	-2.20
Shares Out	6.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,196
Open	468.48
Previous Close	460.00
Day's Range	451.50 - 479.50
52-Week Range	356.00 - 1,355.00
Beta	1.49
Analysts	n/a
Price Target	n/a
Est. Earnings	Sep 25, 2026

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company’s lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic pro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 16
• Stock Exchange: London Stock Exchange
• Ticker Symbol: HEMO

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 25, 2026

Data Sources Report a data error